Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
---|
02/13/2013 | CN102284061B Preparation method of heat-resisting vaccine for domestic animals |
02/13/2013 | CN102159705B Mutant pestivirus with mutations in core gene and ns3 region |
02/13/2013 | CN102100911B Preparation method of Cynoglossus semilaevis vibrio anguillarum vaccine |
02/13/2013 | CN102028941B Neisseria meningitidis group B recombinant protein chimeric vaccine and preparation method thereof |
02/13/2013 | CN101993498B Adenovirus vector avian influenza recombinant vaccine |
02/13/2013 | CN101942417B Separated bacteriophages of enterobacter sakazakii, combination and application thereof |
02/13/2013 | CN101810847B Inflammation-inhibiting compounds |
02/13/2013 | CN101732707B Mercury-free Japanese encephalitis inactivated vaccine composition and application thereof |
02/13/2013 | CN101693742B Anti-IGF-I receptor antibody |
02/13/2013 | CN101559223B Idemic encephalitis diphtheria-pertussis-tetanus combined vaccine |
02/13/2013 | CN101505795B Composition for modulating the expression of cell adhesion molecules |
02/13/2013 | CN101460849B Diagnostic agent and therapeutic agent for pancreatic cancer |
02/13/2013 | CN101405386B Tuberculosis vaccine |
02/13/2013 | CN101394865B Compositions and methods relating to treatment of cancer and infectious diseases |
02/13/2013 | CN101287754B Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
02/13/2013 | CN101282992B 抗肌抑制素抗体 Anti-myostatin antibodies |
02/13/2013 | CN101238209B 登革血清型2减毒株 Save dengue serotype 2 strain |
02/13/2013 | CN101048498B Virosome particles comprising antigens from influenza virus and hepatitis b virus |
02/12/2013 | US8372963 RSV F-protein and its use |
02/12/2013 | US8372958 Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram posiive bacteria |
02/12/2013 | US8372955 Purified antibody to the extracellular domain of NKp44L |
02/12/2013 | US8372798 A stable antibody liquid comprising a precipitated immunoglobulins and water; precipitating with a biocompatible polymer; storage stability |
02/12/2013 | US8372645 Therapeutic composition with a botulinum neurotoxin |
02/12/2013 | US8372622 Modified vaccinia virus ankara for the vaccination of neonates |
02/12/2013 | US8372413 Mycobacterial disease, malaria, leishmaniasis, toxoplasmosis, schistosomiasis and clonorchiasis; antiallergens; asthma |
02/12/2013 | US8372412 Bioassay and peptides for use therein |
02/12/2013 | US8372411 S. pneumoniae antigens |
02/12/2013 | US8372410 S. epidermidis antigens |
02/12/2013 | US8372409 Dendritic cell binding proteins and uses thereof |
02/12/2013 | US8372407 Chimeric HIV fusion proteins as vaccines |
02/12/2013 | US8372406 Antitumoral and antiviral peptides |
02/12/2013 | US8372405 Proteins with improved solubility and methods for producing and using same |
02/12/2013 | US8372404 Anti-C5/C5a antibodies and methods of use |
02/12/2013 | US8372403 Humanized anti-factor D antibodies and uses thereof |
02/12/2013 | US8372402 Mammalian receptor proteins DCRS5; methods of treatment |
02/12/2013 | US8372401 Human antibodies that bind human TNFα |
02/12/2013 | US8372400 Methods of treating disorders using human antibodies that bind human TNFα |
02/12/2013 | US8372399 Bispecific antibodies and agents to enhance stem cell homing |
02/12/2013 | US8372398 Single domain VHH antibodies against Von Willebrand Factor |
02/12/2013 | US8372397 Methods for regulation of stem cells |
02/12/2013 | US8372396 Antibody formulations |
02/12/2013 | US8372393 Method of inducing a CTL response |
02/12/2013 | US8372388 Method for preparing a stable TNF-α vaccine |
02/12/2013 | CA2665707C Method for identification of cellular protein antigens and presence of antibodies to specific cellular protein antigens in serum |
02/12/2013 | CA2548249C Processes for the preparation of a batch of an active pharmaceutical ingredient, a container comprising cryogranules of an allergen product, and a cryogranule of an allergen product |
02/12/2013 | CA2469715C Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
02/12/2013 | CA2462646C Adjuvanted meningococcus compositions |
02/12/2013 | CA2388450C Tadg-15: an extracellular serine protease overexpressed in carcinomas |
02/12/2013 | CA2365903C Viral particles which are released after the infection with the human cytomegalovirus and the use of said particles as a vaccine |
02/12/2013 | CA2345817C Novel methods for therapeutic vaccination |
02/12/2013 | CA2336250C Anti-ccr2 antibodies and methods of use therefor |
02/12/2013 | CA2304350C Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
02/12/2013 | CA2274490C Non-m non-o hiv strains, fragments and applications |
02/11/2013 | DE202012011260U1 Ranibizumab-Spritze Ranibizumab injection |
02/11/2013 | DE202012011259U1 Bevacizumab-Spritze Bevacizumab Injection |
02/07/2013 | WO2013020133A2 Optimized antigens of pneumocystis and use thereof |
02/07/2013 | WO2013020132A1 Methods of treating cardiovascular and metabolic diseases |
02/07/2013 | WO2013020090A2 STREPTOCOCCAL GLcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM |
02/07/2013 | WO2013020074A2 A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin |
02/07/2013 | WO2013019954A1 Method for treating bone gap defects |
02/07/2013 | WO2013019906A1 Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
02/07/2013 | WO2013019889A2 Bovine polyclonal antibody specific for human tnf |
02/07/2013 | WO2013019800A1 Vlps containing ligands and methods related thereto |
02/07/2013 | WO2013019730A1 Antibodies to tip-1 and grp78 |
02/07/2013 | WO2013019710A1 Compositions and methods for the treatment of hiv |
02/07/2013 | WO2013019669A2 Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses |
02/07/2013 | WO2013019648A1 Control of antibody responses to synthetic nanocarriers |
02/07/2013 | WO2013019623A2 Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject |
02/07/2013 | WO2013019603A2 Linear expression cassettes and uses thereof |
02/07/2013 | WO2013019098A1 Helicobacter pylori proteins for diagnostic kit and vaccine |
02/07/2013 | WO2013018894A1 Pharmaceutical composition for treatment and/or prophylaxis of cancer |
02/07/2013 | WO2013018892A1 Drug composition for cancer treatment and/or prevention |
02/07/2013 | WO2013018891A1 Pharmaceutical composition for treatment and/or prophylaxis of cancer |
02/07/2013 | WO2013018889A1 Cancer treatment and/or prevention drug composition |
02/07/2013 | WO2013018886A1 Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
02/07/2013 | WO2013018883A1 Cancer treatment and/or prevention drug composition |
02/07/2013 | WO2013018778A1 Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct |
02/07/2013 | WO2013018018A1 Antitumour combination comprising ombrabulin and cetuximab, associated with radiotherapy |
02/07/2013 | WO2013017713A1 Hrsv f protein in the stabilised pre-fusion state and specific neutralising antibodies against same |
02/07/2013 | WO2013017591A1 Hypoallergenic variants of mal d 1, the major allergen from malus domestica |
02/07/2013 | WO2013017570A1 Novel prrs virus inducing type i interferon in susceptible cells |
02/07/2013 | WO2013017568A1 INFECTIOUS cDNA CLONE OF EUROPEAN PRRS VIRUS AND USES THEREOF |
02/07/2013 | WO2013017540A1 Combination therapy for the treatment of cd19+ b-cell malignancies symptoms comprising an anti-cd19 maytansinoid immunoconjugate and rituximab |
02/07/2013 | WO2013017053A1 Composite vaccine for preventing and treating alzheimer's disease and preparation method therefor |
02/07/2013 | WO2013016805A1 Recombinant swine influenza virus and uses thereof |
02/07/2013 | WO2012134520A3 Regulation of immune response by colocynthin and/or its derivatives |
02/07/2013 | US20130036481 Use of perlecan domain v in treating amyloidogenic disease |
02/07/2013 | US20130035755 Medical device with coating that promotes endothelial cell adherence |
02/07/2013 | US20130035260 Genes involved in inflammatory bowel diseases and use thereof |
02/07/2013 | US20130034610 Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
02/07/2013 | US20130034598 Inhibitors of akt/pkb with anti-tumor activity |
02/07/2013 | US20130034588 Chlamydia pneumoniae associated chronic intraocular disorders and treatment thereof |
02/07/2013 | US20130034587 Methods for treatment of incontinence associated with sexual activity |
02/07/2013 | US20130034585 Bovine Herpes Virus Vaccine With Multiple Mutations |
02/07/2013 | US20130034584 Agent for use in the topical or local treatment of cervical dysplasias |
02/07/2013 | US20130034583 Compositions, methods and uses for expression of enterobacterium-associated peptides |
02/07/2013 | US20130034582 Reverse genetics methods for virus rescue |
02/07/2013 | US20130034581 Genetically engineered swine influenza virus and uses thereof |
02/07/2013 | US20130034580 Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
02/07/2013 | US20130034579 Immunogenic compositions and related methods |